SrilathaEdupugantiMD

[Pronunciation: Sri]

Infectious Disease • Atlanta, GA

Professor, Medicine, Emory University School of Medicine

Join to view full profile

Dr. Edupuganti is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Edupuganti's full profile

Already have an account?

Office
80 Jesse Hill Jr Dr SE
Atlanta, GA 30303
Phone+1 404-778-7717

Education & Training

University of North CarolinaMPH, Epidemiology, 2005
Emory University School of MedicineFellowship, Infectious Disease, 1995 - 1997
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 1992 - 1995
Louisiana State University School of Medicine in New OrleansClass of 1992

Certifications & Licensure

GA State Medical License 1995 - 2025
NC State Medical License 1997 - 2018
LA State Medical License 1994 - 1995

Awards, Honors, & Recognition

HVTN Citizenship Award HIV vaccine trials network, 2019
Paper of the year International Society of Vaccines, 2017
Member of Alpha Omega Alpha Honor Medical Society 1992

Clinical Trials

Human Immune Responses to Yellow Fever Vaccination Start of enrollment: 2008 May 01
Recruiting
Phase 4
Measles, Mumps, and Rubella (MMR) Immunity in College Students Start of enrollment: 2010 Mar 01
Completed
Turnover of Antigen Specific Lymphocytes and Monocytes After Immunization With the 17D Yellow Fever Vaccine Start of enrollment: 2011 Feb 01
Recruiting
Phase 4
Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of the Monoclonal Antibody PGT121.414.LS Administered Alone and in Combination With VRC07-523LS Via Intravenous or Subcutaneous Infusions in Healthy, HIV-uninfected Adult Participants Start of enrollment: 2020 Nov 10
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VR...
Srilatha Edupuganti, Christopher B Hurt, Kathryn E Stephenson, Yunda Huang, Carmen A Paez
The Lancet. HIV. 2024-12-09
Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodies.
William O Hahn, K Rachael Parks, Mingchao Shen, Gabriel Ozorowski, Holly Janes
The Journal of Experimental Medicine. 2024-10-07
Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120.
Zvavahera Mike Chirenje, Fatima Laher, One Dintwe, Monde Muyoyeta, Allan C deCamp
The Journal of Infectious Diseases. 2024-08-16

Press Mentions

Emory University Participating in First-of-Its-Kind HIV Vaccine TrialJuly 21st, 2022
Emory Participating in Trial to Test mRNA HIV Vaccine in HumansJune 7th, 2022
The Only Way We’ll Know When We Need COVID-19 BoostersJune 23rd, 2021
Join now to see all